Firm brings in $10M for cancer therapies

  • By Business Observer Staff
  • | 3:36 p.m. October 10, 2017
  • Tampa Bay-Lakeland
  • Share

TAMPA — Intezyne Technologies, a clinical-stage biopharmaceutical company developing anti-cancer therapies, closed an oversubscribed $10 million Series A Preferred financing round led by existing investor Gaston Capital Healthcare Fund.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • June 5, 2026
The rise and fall of Patrick Britton-Harr: From high-flying entrepreneur to convicted felon
  • June 5, 2026
Tampa developer to bring 2,500 homes to eastern Pasco
  • June 5, 2026
Pennsylvania man convicted of threatening to behead Tampa General CEO
  • June 5, 2026
Meadows Golf Club to open under new management

Sponsored Content